Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction
Shu Kasama, MD*,*,
Takuji Toyama, MD*,
Hisao Kumakura, MD ,
Yoshiaki Takayama, MD,
Shuichi Ichikawa, MD,
Tadashi Suzuki, MD* and
Masahiko Kurabayashi, MD*
* Department of Cardiovascular Medicine, Gunma University School of Medicine, Maebashi, Japan
Cardiovascular Hospital of Central Japan, Gunma, Japan
View larger version (69K):
[in a new window]
|
Figure 1 Representative anterior planar delayed 123I-meta-iodobenzylguandine images before and after treatment from the candesartan group. In this example, the delayed heart/mediastinum count ratios before and after treatment were 1.89 and 2.21, respectively. The washout rates before and after treatment were 45% and 27%, respectively.
|
|
View larger version (70K):
[in a new window]
|
Figure 2 Representative anterior planar delayed 123I-meta-iodobenzylguandine images before and after treatment from the placebo group. In this example, the delayed heart/mediastinum count ratios before and after treatment were 1.93 and 1.81, respectively. The washout rates before and after treatment were 42% and 46%, respectively.
|
|
View larger version (17K):
[in a new window]
|
Figure 3 Changes in the New York Heart Association (NYHA) functional class during treatment in the two groups.
|
|
View larger version (14K):
[in a new window]
|
Figure 4 Correlation between changes in the 123I-meta-iodobenzylguandine scintigraphic findings and the percent change in brain natriuretic peptide (BNP) from baseline to six months in patients receiving candesartan. Delta TDS = total defect score value after six months – pretreatment TDS value; delta H/M ratio = heart/mediastinum count ratio after six months – pretreatment H/M ratio; delta WR = washout rate after six months – pretreatment WR.
|
|
|
